U.S. House Subcommittee Could Discuss 340B on Two Consecutive Days This Month

House Committee on E&C wall plaque
The House Energy & Commerce Health Subcommittee will review a draft drug shortages bill with 340B program implications.

U.S. House Republicans yesterday asked Department of Health and Human Services Secretary Xavier Becerra to testify March 29 about the Biden administration’s health care budget request.

Becerra will appear before the Energy & Commerce health subcommittee the day after it

Read More »

MedPAC’s Call to Replace Medicare DSH Formula Could Spill Over into 340B

MedPAC report to the Congress title page
MedPAC this week recommended replacing the Medicare DSH patient adjustment percentage for Medicare hospital payment purposes. The 340B program uses the same calculation as one of its hospital eligibility criteria.

Congressional Medicare advisers yesterday formally recommended replacing the formula Medicare uses to distribute extra payments to safety net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.

The 340B program uses the same calculation—the Medicare disproportionate share adjustment percentage—to determine eligibility

Read More »

CMS Announces First Drugs Subject to Medicare Inflation Rebates, Issues Guidance Addressing 340B and Medicare Negotiated Drug Prices

CMS building
CMS said planned Medicare Part B premium increases are partly the result of the proposed lump sum payment for previous illegal 340B hospital cuts.

The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, a list that includes AbbVie’s blockbuster arthritis drug Humira, which generated $5.6 billion in global

Read More »

HRSA Wants Reporting Requirements on Use of 340B Savings and Compliance and Reporting Requirements on Use of Contract Pharmacies

HRSA building and signage
HRSA confirmed it will end a pandemic-era waiver program that allowed 340B drug use in certain offsite hospital locations.

The U.S. Health Resources and Services Administration has asked Congress for general rulemaking authority over the 340B program so it can establish “reporting requirements and definitions for the use of [340B] savings and contract pharmacy utilization.”

The Biden administration made

Read More »

340B Prime Vendor Apexus Asks Court to Dismiss AIDS Healthcare Foundation’s Breach of Contract Suit

USDC Central District of California building with Great Seal of the United States
The 340B prime vendor Apexus asked the federal district court in Los Angeles to dismiss AIDS Healthcare Foundation's claims that Apexus failed and refused to negotiate sub-ceiling discounts on HIV/AIDS drugs.

Apexus, the federally contracted 340B prime vendor, asked a federal district judge in Los Angeles on Friday to dismiss AIDS Healthcare Foundation’s lawsuit alleging that Apexus has failed and refused to negotiate sub-ceiling 340B discounts on HIV/AIDS prescription drugs pursuant

Read More »

News Alert

Some Provider Groups Slam NACHC and PhRMA’s 340B Plan, Others Say They’re Studying it

NACHC P&I 2023 speaker at podium
Lt. Cmdr. Emeka Egwim (left), Director of HRSA's Office of Pharmacy Affairs, spoke this morning on 340B Day at NACHC's annual Policy & Issues Forum in Washington, D.C.

A large HIV/AIDS health care group, a Democratic 340B provider ally in Congress, and three national hospital groups lambasted community health centers and drug makers’ historic announcement yesterday that they are working together to remake the 340B program. Other 340B

Read More »

U.S. House Subcommittee Expected to Raise 340B During March 28 Hearing

House E&C wordmark
Provider groups criticized draft legislation to address drug shortages from the House Energy and Commerce Committee.

The Republican-led U.S. House Energy & Commerce health subcommittee late yesterday announced a March 28 hearing on “how transparency and competition can lower health care costs for Americans.”

Although the hearing announcement is silent about the 340B program it

Read More »

Breaking News

Major Drug Industry and Health Center Groups Unite to Reform 340B for Patients and “True” Safety-Net Providers

ASAP 340B wordmark
PhRMA, NACHC, and and the National Hispanic Medical Association created a new group, ASAP 340B, and issued a 10-point plan to ensure that the 340B program “benefits patients and true safety-net providers, including rural hospitals.”

Pharmaceutical Research and Manufacturers of America, the National Association of Community Health Centers, and the National Hispanic Medical Association this morning jointly issued a 10-point plan and created a nonprofit group to ensure that the 340B program “benefits patients and

Read More »

U.S. House Oversight Committee Launches PBM Investigation

House Committee on Oversight and Accountability
A U.S. House committee is investigating “anticompetitive tactics” by Express Scripts, CVS Caremark, and OptumRx.

The U.S. House Committee on Oversight and Accountability last week launched an investigation into how “anticompetitive tactics” by the three largest pharmacy benefit managers—Express Scripts, CVS Caremark, and OptumRx—are driving up healthcare costs and hurting patient care within federal health

Read More »

Amneal Offering 340B Refunds on Long List of Drugs for Sales Between Q3 2019 and Q3 2022

Amneal wordmark on building
Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.

Generic and specialty drug manufacturer Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.

The U.S. Health Resources and Services Administration posted New Jersey-based Amneal’s notice to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report